Practice Management News

Factors for risk for rehospitalization for those with psychiatric disorders included suicidal ideation, suicide attempt, previous hospitalization and longer stay in hospital, according to a study published in BMC Psychiatry.

People experiencing persistent post-concussion symptoms were at a higher risk for depressive symptoms, researchers reported in JAMA Network Open.

A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003for treatment-resistant depression.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.

We compiled a list of stories involving substance use and children that were published in 2022.

A new national telehealth program called Crisis Care has been created to treat individuals with elevated suicide risk, a release from Brightside Health stated.

Boehringer Ingelheim and Click Therapeutics have announced the launch of an expanded collaboration for development and commercialization of a second prescription digital therapeutic for those diagnosed with schizophrenia.

The American Academy of Family Physicians said it is “disappointed” that the end-of-year congressional spending bill “fails to adequately address outdated Medicare physician payment.”

KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder.

Traumatic brain injury, PTSD and the apolipoprotein E4 gene showed strong associations with Alzheimer’s disease and related dementias, researchers reported in Alzheimer’s & Dementia.